Results of treatment of 44 patients with disseminated non-seminomatous testicular tumors versus advancement are discussed in the paper. In cases of minimal and moderate advancement (group 1), induction chemotherapy included three cycles of VAB-6 regimen (vinblastine, actinomycin D, bleomycetin, cyclophosphamide plus 120 mg/m2 platidiam) whereas cases of advanced tumor (group 2) received six such cycles; two of them used 150 mg/m2 platidiam dropwise in a 3% sodium chloride solution. Complete regression was observed in 22 of 24 (96.1%) patients of group 1 and in seven out of 20 (35%) cases of group 2; it was registered in 100, 81.8 and 38% of patients with minimal, moderately- and far-advanced disease, respectively. Patients were followed for 4-23 months (average 14.5 months). Eight cases relapsed. At the time of this writing, 38 out of 44 (86.3%) patients are alive, and 23 out of 29 (79.3%) continue in complete remission. Toxicity was moderate. Application of 3% NaCl prevented nephrotoxicity of high-dose (150 mg/m2) platidiam.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Efficacy, safety, and multi-omics analysis of pembrolizumab combined with nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: A single-arm phase 2 study.
Chin J Cancer Res
December 2024
Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China.
Objective: Based on the findings of the KEYNOTE-048 study, pembrolizumab in combination with platinum and fluorouracil is the standard first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). The efficacy and safety of pembrolizumab combined with nab-paclitaxel and platinum in such patients remain unexplored.
Methods: This single-arm phase 2 study enrolled patients with R/M HNSCC who received pembrolizumab (200 mg), nab-paclitaxel (260 mg/m²), and either cisplatin (75 mg/m²) or carboplatin [area under the curve (AUC) 5] every 21 d for up to six cycles, followed by pembrolizumab maintenance therapy.
Pemetrexed Maintenance versus Observation in Patients with Advanced Urothelial Carcinoma Who Completed First-line Platinum-based Chemotherapy without Disease Progression (PREMIER, KCSG GU16-05).
Cancer Res Treat
December 2024
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Purpose: Platinum-based chemotherapy is the standard treatment for advanced urothelial carcinoma (aUC). Switch maintenance therapy after first-line (1L) treatment may delay disease progression. This study evaluated pemetrexed as switch maintenance therapy versus observation in aUC patients without disease progression after initial chemotherapy.
View Article and Find Full Text PDFPhase I clinical trial testing the dose escalation and expansion of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin administration (PITHAC) for the management of pleural carcinosis.
Cancer Treat Res Commun
December 2024
Division of Thoracic Surgery, University Hospital of Lausanne, Rue du Bugnon 46 1011, Lausanne, Switzerland. Electronic address:
Background: Pleural carcinosis originates from various cancers. Its management consists in systemic therapies combined to dyspnea relief procedures. Prior studies have tested hyperthermic intrathoracic chemotherapy to treat pleural carcinosis with interesting patient survival results.
View Article and Find Full Text PDFPhase II Trial of Neoadjuvant Docetaxel/Cisplatin/5-Fluorouracil Combined with Pegteograstim for Unresectable, Locally Advanced Sinonasal Squamous Cell Carcinoma: KCSG HN18-07.
Cancer Res Treat
December 2024
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Purpose: The role of neoadjuvant chemotherapy in locally advanced sinonasal squamous cell carcinoma (SNSCC) has not been established prospectively. We conducted a phase II trial of neoadjuvant chemotherapy (NAC) with docetaxel/cisplatin/5-fluorouracil (TPF) in this population.
Materials And Methods: Eligible patients had unresectable, locally advanced SNSCC, defined as T3/4 stage or potential compromise of critical organ function on surgery.
Is there a role of cytoreductive surgery with HIPEC in recurrent ovarian granulosa cell tumors? An Indian cancer center experience with review of literature.
Indian J Cancer
January 2024
Department of Surgical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Article Synopsis
- Granulosa cell tumors (GCTs) are common ovarian tumors associated with a good prognosis but a tendency for late recurrences, making treatment difficult.
- A study evaluated the effects of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) on eight patients with recurrent adult GCTs, showing a median overall survival of 11.5 months post-treatment.
- The procedure demonstrated acceptable levels of postoperative complications, but more research is needed to confirm its effectiveness as a treatment option for recurrent GCTs.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!